196 related articles for article (PubMed ID: 31181214)
1. Attenuation of frailty in older adults with mesenchymal stem cells.
Florea V; Bagno L; Rieger AC; Hare JM
Mech Ageing Dev; 2019 Jul; 181():47-58. PubMed ID: 31181214
[TBL] [Abstract][Full Text] [Related]
2. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics.
Zhu Y; Ge J; Huang C; Liu H; Jiang H
Theranostics; 2021; 11(12):5675-5685. PubMed ID: 33897874
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
Golpanian S; DiFede DL; Pujol MV; Lowery MH; Levis-Dusseau S; Goldstein BJ; Schulman IH; Longsomboon B; Wolf A; Khan A; Heldman AW; Goldschmidt-Clermont PJ; Hare JM
Oncotarget; 2016 Mar; 7(11):11899-912. PubMed ID: 26933813
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty.
Mahindran E; Law JX; Ng MH; Nordin F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638883
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stem Cell Therapy for Aging Frailty.
Schulman IH; Balkan W; Hare JM
Front Nutr; 2018; 5():108. PubMed ID: 30498696
[TBL] [Abstract][Full Text] [Related]
6. Clinical Study of Mesenchymal Stem/Stromal Cell Therapy for the Treatment of Frailty: A Proposed Experimental Design for Therapeutic and Mechanistic Investigation.
Hoang DM; Nguyen KT; Hoang VT; Dao LTM; Bui HT; Ho TTK; Nguyen TTP; Ngo ATL; Nguyen HK; Thanh LN
J Gerontol A Biol Sci Med Sci; 2022 Jul; 77(7):1287-1291. PubMed ID: 34718548
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal Stem Cells for Frailty?
Larrick JW; Mendelsohn AR
Rejuvenation Res; 2017 Dec; 20(6):525-529. PubMed ID: 29179649
[TBL] [Abstract][Full Text] [Related]
8. Frailty and Rejuvenation with Stem Cells: Therapeutic Opportunities and Clinical Challenges.
Sun XL; Hao QK; Tang RJ; Xiao C; Ge ML; Dong BR
Rejuvenation Res; 2019 Dec; 22(6):484-497. PubMed ID: 30693831
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal Stem Cell Transplantation for the Treatment of Cognitive Frailty.
Lv X; Niu H
J Nutr Health Aging; 2021; 25(6):795-801. PubMed ID: 34179936
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Tompkins BA; DiFede DL; Khan A; Landin AM; Schulman IH; Pujol MV; Heldman AW; Miki R; Goldschmidt-Clermont PJ; Goldstein BJ; Mushtaq M; Levis-Dusseau S; Byrnes JJ; Lowery M; Natsumeda M; Delgado C; Saltzman R; Vidro-Casiano M; Da Fonseca M; Golpanian S; Premer C; Medina A; Valasaki K; Florea V; Anderson E; El-Khorazaty J; Mendizabal A; Green G; Oliva AA; Hare JM
J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1513-1522. PubMed ID: 28977399
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
Golpanian S; DiFede DL; Khan A; Schulman IH; Landin AM; Tompkins BA; Heldman AW; Miki R; Goldstein BJ; Mushtaq M; Levis-Dusseau S; Byrnes JJ; Lowery M; Natsumeda M; Delgado C; Saltzman R; Vidro-Casiano M; Pujol MV; Da Fonseca M; Oliva AA; Green G; Premer C; Medina A; Valasaki K; Florea V; Anderson E; El-Khorazaty J; Mendizabal A; Goldschmidt-Clermont PJ; Hare JM
J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1505-1512. PubMed ID: 28444181
[TBL] [Abstract][Full Text] [Related]
12. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion.
Vanitallie TB
Metabolism; 2003 Oct; 52(10 Suppl 2):22-6. PubMed ID: 14577059
[TBL] [Abstract][Full Text] [Related]
13. The Case for Stage-Specific Frailty Interventions Spanning Community Aging to Cognitive Impairment.
Chong MS; Tay L; Ismail NH; Tan CH; Yew S; Yeo A; Ye R; Leung B; Ding YY
J Am Med Dir Assoc; 2015 Nov; 16(11):1003.e13-9. PubMed ID: 26543008
[TBL] [Abstract][Full Text] [Related]
14. Aging clinical problems: a difficult balance between age and frailty.
Rozzini R
Monaldi Arch Chest Dis; 2016 Jun; 84(1-2):727. PubMed ID: 27374041
[TBL] [Abstract][Full Text] [Related]
15. Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults.
Angulo J; El Assar M; Rodríguez-Mañas L
Mol Aspects Med; 2016 Aug; 50():1-32. PubMed ID: 27370407
[TBL] [Abstract][Full Text] [Related]
16. Biology of frailty: Implications for clinical pharmacology and drug therapy in frail older people.
Hilmer SN; Wu H; Zhang M
Mech Ageing Dev; 2019 Jul; 181():22-28. PubMed ID: 31125572
[TBL] [Abstract][Full Text] [Related]
17. Physical frailty and sarcopenia (PF&S): a point of view from the industry.
Del Signore S; Roubenoff R
Aging Clin Exp Res; 2017 Feb; 29(1):69-74. PubMed ID: 28160253
[TBL] [Abstract][Full Text] [Related]
18. Nutrition and Exercise in Sarcopenia.
Anton SD; Hida A; Mankowski R; Layne A; Solberg LM; Mainous AG; Buford T
Curr Protein Pept Sci; 2018; 19(7):649-667. PubMed ID: 28029078
[TBL] [Abstract][Full Text] [Related]
19. Frailty Screening in the Community Using the FRAIL Scale.
Woo J; Yu R; Wong M; Yeung F; Wong M; Lum C
J Am Med Dir Assoc; 2015 May; 16(5):412-9. PubMed ID: 25732832
[TBL] [Abstract][Full Text] [Related]
20. Differential association of frailty with cognitive decline and sarcopenia in community-dwelling older adults.
Nishiguchi S; Yamada M; Fukutani N; Adachi D; Tashiro Y; Hotta T; Morino S; Shirooka H; Nozaki Y; Hirata H; Yamaguchi M; Arai H; Tsuboyama T; Aoyama T
J Am Med Dir Assoc; 2015 Feb; 16(2):120-4. PubMed ID: 25244957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
